Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

The CCR5 Delta 32 Polymorphism in Brazilian Patients with Sickle Cell Disease

Texto completo
Autor(es):
Mostrar menos -
Lopes, Mariana Pezzute [1] ; Nunes Santos, Magnun Nueldo [1] ; Faber, Eliel Wagner [1] ; Cavalcanti Bezerra, Marcos Andre [2] ; Domingues Hatzlhofer, Betania Lucena [2] ; Albuquerque, Dulcineia Martins [3] ; Zaccariotto, Tania Regina [1] ; Ribeiro, Daniela Maria [1] ; Araujo, Aderson da Silva [2] ; Costa, Fernando Ferreira [3] ; Sonati, Maria de Fatima [1]
Número total de Autores: 11
Afiliação do(s) autor(es):
[1] State Univ Campinas UNICAMP, Sch Med Sci, Dept Clin Pathol, BR-13083970 Campinas, SP - Brazil
[2] HEMOPE Fdn, Pernambuco Hematol & Hemotherapy Ctr, BR-52011900 Recife, PE - Brazil
[3] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, BR-13083878 Campinas, SP - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: DISEASE MARKERS; 2014.
Citações Web of Science: 3
Resumo

Background. Previous studies on the role of inflammation in the pathophysiology of sickle cell disease (SCD) suggested that the CCR5 Delta 32 allele, which is responsible for the production of truncated C-C chemokine receptor type 5 (CCR5), could confer a selective advantage on patients with SCD because it leads to a less efficient Th1 response. We determined the frequency of the CCR5 Delta 32 polymorphism in 795 Afro-Brazilian SCD patients followed up at the Pernambuco Hematology and Hemotherapy Center, in Northeastern Brazil, divided into a pediatric group (3 months-17 years, n = 483) and an adult group (18-70 years, n = 312). The adult patients were also compared to a healthy control group (blood donors, 18-61 years, n = 247). Methods. The CCR5/CCR5 Delta 32 polymorphism was determined by allele-specific PCR. Results. No homozygous patient for the CCR5 Delta 32 allele was detected. The frequency of heterozygotes in the study population (patients and controls) was 5.8%, in the total SCD patients 5.1%, in the children 5.4%, in the adults with SCD 4.8%, and in the adult controls 8.1%. These differences did not reach statistical significance. Conclusions. Our findings failed to demonstrate an important role of the CCR5 Delta 32 allele in the population sample studied here. (AU)

Processo FAPESP: 08/57441-0 - Alterações clínicas, celulares e moleculares nas hemoglobinopatias e em outras anemias hemolíticas hereditárias
Beneficiário:Fernando Ferreira Costa
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 11/02622-3 - Aspectos inflamatórios versus genótipos da haptoglobina e da hemopexina e presença do polimorfismo ccr5d32 na anemia falciforme
Beneficiário:Maria de Fatima Sonati
Linha de fomento: Auxílio à Pesquisa - Regular